AU764992B2 - TNF-derived peptides for use in treating oedema - Google Patents

TNF-derived peptides for use in treating oedema Download PDF

Info

Publication number
AU764992B2
AU764992B2 AU56209/99A AU5620999A AU764992B2 AU 764992 B2 AU764992 B2 AU 764992B2 AU 56209/99 A AU56209/99 A AU 56209/99A AU 5620999 A AU5620999 A AU 5620999A AU 764992 B2 AU764992 B2 AU 764992B2
Authority
AU
Australia
Prior art keywords
tnf
peptide
oedema
peptides
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU56209/99A
Other languages
English (en)
Other versions
AU5620999A (en
Inventor
Alain Bloc
Patrick De Baetselier
Lucie Fransen
Rudolf Lucas
Jerome Pugin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lucas Rudolf Dr
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of AU5620999A publication Critical patent/AU5620999A/en
Application granted granted Critical
Publication of AU764992B2 publication Critical patent/AU764992B2/en
Assigned to LUCAS, Rudolf Dr. reassignment LUCAS, Rudolf Dr. Alteration of Name(s) in Register under S187 Assignors: INNOGENETICS N.V.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU56209/99A 1998-08-14 1999-08-10 TNF-derived peptides for use in treating oedema Ceased AU764992B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870198 1998-09-18
EP98870222 1998-10-21
EP98870222 1998-10-21
PCT/EP1999/005806 WO2000009149A1 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Publications (2)

Publication Number Publication Date
AU5620999A AU5620999A (en) 2000-03-06
AU764992B2 true AU764992B2 (en) 2003-09-04

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56209/99A Ceased AU764992B2 (en) 1998-08-14 1999-08-10 TNF-derived peptides for use in treating oedema

Country Status (20)

Country Link
US (2) US20030105021A1 (enExample)
EP (3) EP1247531B1 (enExample)
JP (1) JP4542266B2 (enExample)
CN (1) CN1181886C (enExample)
AT (2) ATE395072T1 (enExample)
AU (1) AU764992B2 (enExample)
BR (1) BR9912899A (enExample)
CA (1) CA2334941C (enExample)
CZ (1) CZ302862B6 (enExample)
DE (2) DE69938743D1 (enExample)
DK (1) DK1264599T3 (enExample)
ES (1) ES2296872T3 (enExample)
HU (1) HU227661B1 (enExample)
IL (2) IL141064A0 (enExample)
NZ (1) NZ509604A (enExample)
PL (1) PL203706B1 (enExample)
PT (1) PT1264599E (enExample)
TR (1) TR200100338T2 (enExample)
WO (1) WO2000009149A1 (enExample)
ZA (1) ZA200100656B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema
EP1781323B1 (en) 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
JP6335279B2 (ja) * 2013-04-23 2018-05-30 アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー 式ｘ１−ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ−ｘ２の環状ペプチドを含んでなる医薬組成物および体外肺処置のための使用
JP6397984B2 (ja) 2014-03-18 2018-09-26 アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＡｐｅｐｔｉｃｏ Ｆｏｒｓｃｈｕｎｇ Ｕｎｄ Ｅｎｔｗｉｃｋｌｕｎｇ Ｇｍｂｈ 乾燥粉末ペプチド医薬
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
EP4051307B1 (en) 2020-05-08 2023-02-01 APEPTICO Forschung und Entwicklung GmbH Peptide for prevention or treatment of covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
NZ509604A (en) 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REZAIGUIA ET AL. J.CLINT.INVEST., (1997), 99(2), 325-335 *

Also Published As

Publication number Publication date
DK1264599T3 (da) 2008-02-04
JP4542266B2 (ja) 2010-09-08
EP1247531A2 (en) 2002-10-09
EP1264599A1 (en) 2002-12-11
PL345997A1 (en) 2002-01-14
ZA200100656B (en) 2005-06-29
IL141064A0 (en) 2002-02-10
EP1105152A1 (en) 2001-06-13
ATE395072T1 (de) 2008-05-15
EP1247531B1 (en) 2008-05-14
CA2334941A1 (en) 2000-02-24
BR9912899A (pt) 2001-05-08
PT1264599E (pt) 2008-01-07
IL141064A (en) 2009-09-01
PL203706B1 (pl) 2009-11-30
HU227661B1 (hu) 2011-10-28
NZ509604A (en) 2003-05-30
TR200100338T2 (tr) 2001-12-21
US7258861B2 (en) 2007-08-21
CZ302862B6 (cs) 2011-12-21
CN1312724A (zh) 2001-09-12
EP1264599B1 (en) 2007-09-26
DE69938743D1 (de) 2008-06-26
HUP0103117A2 (hu) 2001-12-28
US20030105021A1 (en) 2003-06-05
DE69937206T2 (de) 2008-06-19
DE69937206D1 (de) 2007-11-08
CZ2001538A3 (cs) 2001-08-15
HUP0103117A3 (en) 2004-03-01
EP1247531A3 (en) 2002-12-18
JP2002522508A (ja) 2002-07-23
CN1181886C (zh) 2004-12-29
ATE374039T1 (de) 2007-10-15
CA2334941C (en) 2011-08-09
ES2296872T3 (es) 2008-05-01
HK1051805A1 (en) 2003-08-22
AU5620999A (en) 2000-03-06
WO2000009149A1 (en) 2000-02-24
US20030185791A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AU764992B2 (en) TNF-derived peptides for use in treating oedema
US11066458B2 (en) VEGF antagonist formulations suitable for intravitreal administration
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US5238919A (en) Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
US9555080B2 (en) Medicament for therapeutic treatment and/or improvement of sepsis
KR20030060988A (ko) 펩타이드 및/또는 단백질, 및 치료제 및 예방제의 제조를위한 그들의 용도
JPH07509691A (ja) 安定なポリペプチド組成物
WO2013162078A1 (ja) 上皮及び内皮損傷の治療剤
HK1051802A (en) Tnf-derived peptides for use in treating oedema
HK1051805B (en) Tnf-derived peptides for use in treating oedema
MXPA01001527A (en) Tnf-derived peptides for use in treating oedema
CN101730710A (zh) Vegf-d突变体及其用途
WO2012081711A1 (ja) 細胞遊走調節剤
PT99632B (pt) Processo para a preparacao de uma substancia de ligacao de trombina

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)